AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class first
admin 26th February 2019 Uncategorised 0AstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. The companies said Tuesday their PARP inhibitor topped placebo at staving off progression of notoriously tough-to-treat pancreatic cancer. More:
read more